2 Infusion of LPS (5 µg/ml) caused a rapid and sustained fall in coronary perfusion pressure (PP) of 59 ± 4 mmHg (n = 12) and a biphasic increase in NO levels determined in the coronary effluent by chemiluminescent detection. Both the fall in PP and the increase in NO release were completely abolished (n = 3) by pre-treatment of hearts with the NO synthase inhibitor L-NAME (50 µM).
Introduction
Nitric oxide (NO) synthesised by inducible NO synthase has been identified as an important mediator of the marked hypotension and hyporeactivity to vasoconstrictor agents induced by bacterial lipopolysaccharide (LPS) in experimental models of endotoxemia (Kilbourn et al., 1990; Thiemermann & Vane, 1990) . Although the role of constitutive NO synthase in this disease state still remains to be established, it has become apparent that LPS may also activate this pathway (Thiemermann & Vane, 1990) with the released NO accounting, at least in part, for the initial fall in mean arterial pressure observed in vivo. In this regard we have previously demonstrated that infusion of LPS through the rat isolated perfused heart causes a rapid fall in coronary perfusion pressure (Baydoun et al., 1993) . This acute vasodilator response was endothelium-dependent and blocked by inhibitors of nitric oxide (NO) synthase including L-N G -nitro-L-arginine methylester (L-NAME), strongly suggesting that LPS acutely releases NO, presumably via the constitutive L-arginine-NO pathway.
We have now extended these studies by examining whether LPS activates constitutive NO synthase directly or via intermediate pathways. It is worth noting that both bradykinin and platelet activating factor (PAF) may be released acutely following administration of LPS in vivo (Doebber et al., 1985; Katori et al., 1989) . Furthermore, PAF produces a similar in vivo hypotensive response to that caused by LPS (Bessin et al., 1983; Doebber et al., 1985; Mulder et al., 1993) and both bradykinin and PAF antagonists have been reported to attenuate the acute hypotensive response to LPS (Doebber et al., 1985; Wilson et al., 1989) .
We have therefore examined the effects of the potent and selective kinin B 2 receptor antagonist D-Arg- [Hyp 3 , Thi 5 , D-Tic 7 , Oic 8 ] bradykinin (HOE-140) (Lembeck et al., 1991) and the PAF antagonist WEB 2086 (Casals-Stenzel et al., 1986) on LPS-induced 5 vasodilatation in the rat isolated perfused heart. We have also examined the role of PLA 2 -derived mediators other than PAF in the response to LPS.
In our previous study (Baydoun et al., 1993) dexamethasone (10 µM) completely abolished the acute coronary vasodilatation caused by LPS. This finding was of interest because dexamethasone has previously only been shown to inhibit expression of the inducible isoform of NO synthase whilst having no effect on the constitutive enzyme or the activity of inducible NO synthase once expressed (Radomski et al., 1990) . We have therefore further examined this finding by investigating both the concentration and time dependency of the action of dexamethasone and its antagonism by the glucocorticoid receptor antagonist, RU-486. Using a selective lipocortin 1 (LC1)-neutralising antibody, LCPS1 (Perretti et al., 1996) , we have explored whether the actions of dexamethasone are mediated by LC1, a member of the annexin family which is strongly induced by glucocorticoids and accounts, at least in part, for the pharmacological actions of dexamethasone (Flower & Rothwell, 1994) .
Methods

Isolation and perfusion of rat heart
Hearts from male Sprague-Dawley rats (≥ 250g) were perfused as described previously (Baydoun et al., 1993) by a modified Langendorff technique similar to that described by Broadley (1979) at a constant flow of 10 ml.min -1 with Krebs-Henseleit buffer (composition (mM): NaCl, 118; NaHCO 3 , 25; D-glucose, 11; KCl, 4.7; MgSO 4 , 1.2; KH 2 PO 4 , 1.1) maintained at 37 ºC and gassed with 95 % O 2 /5% CO 2. Following an equilibration period of at least 20 min, basal coronary vascular tone (56 ± 4 mmHg; n = 12) was elevated (113 ± 8 mmHg; n=12) by infusion of the thromboxane mimetic 9,11-dideoxy-11α,9α-epoxymethano-6 prostaglandin F 2α (U46619; 5 nM). Bolus injections of bradykinin (0.1 nmol) or sodium nitroprusside (SNP; 10 nmol) were administered into the perfusion line 3 cm proximal to the heart. All other agents, including LPS, were added to the buffer reservoir and perfused through the coronary vasculature.
Chemiluminescent detection of nitric oxide
Release of NO into the coronary effluent was monitored by chemiluminescent detection using a Sievers NO analyser (model 280A, Sievers instruments Inc. Boulder CO, USA), as previously described (Menon et al., 1989) . In these studies, coronary flow was reduced to 1 ml min -1 in order to concentrate amounts of nitrite/nitrate released into the effluent. This was carried out in a stepwise manner by reducing flow from 10 to 8, 5, 3 and 1 ml.min -1 , allowing the heart to equilibrate for 10 min at each reduced flow rate. This protocol did not result in any impairment of myocardial function, since when flow was restored to 10 ml.min -1 , cardiac contractility, vascular tone and heart rate returned to their normal values prior to reducing flow.
After equilibration at 1 ml min -1 aliquots of effluent (0.5 ml) were collected prior to (control sample) and at approximately 3 min intervals following perfusion of LPS (5 μg ml -1 ) over a period of 60 min. In time-matched controls hearts were perfused with Krebs buffer alone. Samples were immediately frozen at -20 ºC until analysed. Nitrite and nitrate, the stable oxidation products of NO in the heart (Kelm & Schrader, 1990) , were converted to NO by injecting 2-10 μl of effluent into a vessel containing a reducing solution of vanadium(III) chloride in HCl. Liberated NO was then purged from solution by bubbling with nitrogen under reduced pressure and analysed by reaction with ozone. This reaction yields light, the intensity of which was recorded using a cooled red-sensitive photomultiplier tube. 
Statistical analysis
Results are expressed as mean ± s.e. mean for n experiments. Statistical analyses were performed using a multiple means comparison test (Harper, 1984) validated by comparison with the Newman-Keuls multiple range test in the statistical package SPP (Royston, 1984) with the overall confidence levels set at 99% (0.01).
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Results
Involvement of nitric oxide in LPS-induced coronary vasodilatation
Consistent with our previous studies (Baydoun et al., 1993) , LPS (5 µg.ml -1 ) caused a rapid fall in perfusion pressure (PP) of 59 ± 4 mmHg (n=12). This response was maximal within 5 minutes and maintained over a prolonged period (> 90 min) during continued LPS infusion. In parallel experiments, chemiluminescent analysis of coronary effluent revealed a marked increase in NO release 3 min after introducing LPS and by 6 min this had declined again, but was still higher than basal values (Fig 1) . Moreover, NO production was maintained at the lower plateau level over the 60 min period of LPS perfusion. No significant change above basal was detected in effluent collected from hearts perfused with Krebs buffer alone.
Termination of LPS infusion resulted in rapid reversal of the vasodilator response, with vascular tone returning to the pre-LPS level within 3 min after cessation of LPS perfusion.
Stimulated NO production also decreased rapidly to basal levels following LPS washout. In addition, perfusion of hearts with L-NAME (50 µM) abolished the vasodilator response and release of NO caused by LPS, but did not alter the response to SNP and reduced the duration but not the magnitude of the response to bradykinin (Table 1) .
Effects of HOE-140 on LPS-induced vasodilatation
Pre-perfusion of hearts with the selective kinin B 2 receptor antagonist HOE-140 (100 nM) caused a small but significant increase in PP of 19 ± 8 mmHg (n = 3; p < 0.05). More importantly, HOE pre-treatment completely abolished the vasodilator response to a maximal concentration of bradykinin (0.1 nmol) and markedly attenuated LPS-induced vasodilatation, reducing the latter by 92 ± 6 % (n=3). In contrast, HOE-140 had no effect on the vasodilatation induced by SNP (10 nmol) confirming its selectivity of action (Fig 2) .
Role of PLA 2, PAF and lipoxygenase products in LPS-induced vasodilatation
Experiments were carried out employing mepacrine, an effective but non-selective inhibitor of PLA 2 , to ascertain whether activation of PLA 2 also contributes to the response to LPS. In these studies, mepacrine (0.5 μM, 30 min pre-perfusion) selectively blocked LPSinduced vasodilatation but had no direct effect on coronary tone or on the magnitude and duration of responses to either bradykinin (0.1 nmol) or SNP (10 nmol) ( Table 2) .
We have previously shown that indomethacin has no significant effect on the acute actions of LPS in the rat heart (Baydoun et al., 1993) , current studies were therefore focused on other PLA 2 -dependent pathways. Studies involving PAF itself proved difficult to interpret for several reasons. Firstly, responses to PAF were quite variable. Secondly, a single administration of PAF, even at very low doses (10 -21 to 10 -7 mol), resulted in marked and rapid desensitisation to subsequent applications (data not shown). However, experiments carried out using the PAF receptor antagonist WEB 2086 revealed that LPS-induced vasodilatation was at least in part PAF dependent, since it was attenuated by WEB 2086. A 30 min pre-perfusion of hearts with WEB 2086 (3 μM) reduced the LPS-induced fall in PP by 70 ± 8% (n = 4) whilst having no effect on coronary tone or on either bradykinin (0.1 nmol) or SNP (10 nmol) induced vasodilatation (Table 2) .
In contrast to indomethacin, pre-perfusion of hearts with nordihydroguaiaretic acid (NDGA), an inhibitor of lipoxygenase enzymes (Slapke et al., 1983) , at a concentration of 0.1 μM for 30 min, significantly decreased the vasodilator action of LPS in the rat heart.
Under these conditions, NDGA reduced the LPS-induced fall in PP by 86 ± 5% (n = 4) but 10 failed to modify either bradykinin (0.1 nmol) or SNP (10 nmol) induced changes in vascular tone (Table 2) . Coronary perfusion pressure was also unaffected by NDGA.
Inhibition of LPS-induced vasodilatation by dexamethasone
Pre-treatment of hearts with dexamethasone caused marked attenuation of LPS-induced vasodilatation at 1 nM and complete inhibition at concentrations of 0.1, 1 and 10 μM. This effect was time-dependent: when administered simultaneously with or for 5 min prior to LPS, dexamethasone (1 nM) failed to significantly alter the response to LPS; in contrast, pretreatment of hearts for 15 or 30 min attenuated the vasodilatation induced by LPS by 92 ± 1 % (n=3) and 89 ± 3 % (n=3), respectively (Fig. 3) . Under similar conditions progesterone was without effect even at 1 µM (data not shown).
The inhibition caused by dexamethasone (1 nM, 15 min perfusion) was completely blocked when hearts were pre-treated for 15 minutes with the glucocorticoid receptor antagonist RU-486 (100 nM) prior to administration of dexamethasone (1 nM). In these studies, responses to LPS (5 μg ml -1 ) were not significantly different from those observed in controls (Fig 4) .
The role of lipocortin 1 in the inhibitory action of dexamethasone
To establish whether the action of dexamethasone involves LC1, experiments were conducted with a selective polyclonal neutralising anti-LC1 antibody (LCPS1) raised in sheep against the N-terminus of LC1 (Perretti et al., 1996) . Hearts were pre-perfused for 2 min with a 1:200 dilution of LCPS1 prior to administration of dexamethasone (1 nM; 15 min) and subsequently LPS (5μg.ml -1 ). Another sheep anti-lipocortin 1 antibody (LCPS2), which recognises the protein but does not neutralise it (Perretti et al., 1996) was used as a control.
LCPS1 pre-treatment did not alter vascular tone but markedly attenuated the inhibitory action of dexamethasone, restoring LPS-induced vasodilatation to 66 ± 12 % of the control response. The non-neutralising antibody, LCPS2, was without effect (Fig 4) .
Selective inhibition of LPS-induced vasodilatation by cycloheximide
Since the actions of dexamethasone apparently involved induction of synthesis and/or
translocation of LC1, we tested the effects of cycloheximide on the LPS-induced fall in coronary perfusion pressure. Surprisingly, pre-perfusion of cycloheximide (10µM, 15 min) alone completely abolished responses to LPS (5 μg ml -1 , Fig.5 ). Thus, further experiments involving cycloheximide and dexamethasone could not be carried out. At 10 μM, cycloheximide had no effect on basal tone nor did it cause any statistically significant change in the responses to either bradykinin (0.1 nmol) or SNP (10 nmol).
Discussion
These data confirm that perfusion of LPS through rat isolated hearts elicits a rapid and maintained vasodilatation. As reported previously (Baydoun et al., 1993) this response is blocked by L-NAME, implicating NO as a potential mediator. However, substituted arginine analogues such as L-NAME and N G -monomethyl-L-arginine (L-NMMA) can have effects other than inhibition of nitric oxide synthase (Cocks & Angus, 1991) , and may even cause increased release of NO (Archer & Hampi, 1992) . To confirm unequivocally whether LPS causes NO released from the rat isolated perfused heart we monitored NO production by measuring levels of nitrite and nitrate, stable end products of NO metabolism, using chemiluminescence detection. These experiments revealed that LPS infusion was accompanied by a biphasic increase in release of nitrate and nitrite of which the amounts produced over the first 3 min of perfusion are at least six times higher than those maintaining the plateau phase. The reason for the biphasic nature of LPS-induced NO release is not clear.
There is no correlating biphasic vasodilatation to LPS. However it may be that both the initial peak and the plateau of NO production are sufficient to cause maximal and maintained dilatation. Since both coronary vasodilatation and NO release were blocked by L-NAME it can be concluded that the action of L-NAME in reducing LPS-induced vasodilatation is due to inhibition of NO synthesis.
In addition to NO release our study has also implicated bradykinin production in LPSinduced coronary vasodilatation. This effect is mediated by kinin B 2 -receptors, since it was abolished by HOE 140. These findings are supported by other studies demonstrating that bradykinin antagonists block the acute phase of LPS-induced hypotension in vivo (Katori et al., 1989; Wilson et al., 1989) , and inhibit the rapid release of NO from cultured endothelial cells exposed to LPS (Fleming et al., 1992) . Further studies in rats deficient in kininogens, the physiological precursor of bradykinin, have revealed that the hypotensive response to exogenous bradykinin was unchanged, but the biphasic response to LPS was markedly altered in that the second, phase (70-80 min after LPS) was conserved, but the first phase (~15 min after LPS) was abolished. The same profile of inhibition was seen following HOE 140-treatment in kininogen-replete rats (Ueno et al., 1995) . Thus bradykinin is an important mediator of the acute vasodilator response to LPS and may be released locally following stimulation.
Although the precise mechanism of action of bradykinin still remains to be established, it is evident that its vasodilator action in the rat heart is mediated, at least in part, via NO synthesis following activation of endothelial constitutive NO synthase (Baydoun & Woodward, 1991) . Thus, LPS-induced NO production in this study may be secondary to the 13 release of bradykinin since both responses are abolished by HOE 140. Interestingly, L-NAME completely abolished vasodilatation to LPS but only partially inhibited responses to exogenous bradykinin, reducing the duration while having no significant effect on the magnitude of the response. This observation is consistent with the hypothesis that exogenous bradykinin exerts a biphasic effect in the rat heart of which only the second phase is NO mediated (Baydoun & Woodward, 1991) . Furthermore, our findings raise the possibility that the effects of endogenous and exogenous bradykinin may be mediated differently. In this regard, Hecker et al. (1993; In addition to the established involvement of NO, additional data obtained with mepacrine, WEB 2086 and NDGA suggest that the acute vasodilator response to LPS is complex and dependent on multiple mediators. Although the precise link remains to be established, it is evident from our data that both the NO synthase and PLA 2 pathways are involved. The inhibition of LPS-induced vasodilatation by relatively low concentrations of mepacrine strongly suggests that PLA 2 activation contributes to this response. This is further supported by data obtained in the presence of dexamethasone which inhibits PLA 2 activation in a variety of cells and tissues (Burch, 1990; Lilja et al., 1994) . In our study pre-perfusion of hearts with dexamethasone for as little as 15 min virtually abolished the vasodilator response to LPS. Furthermore this effect was observed with concentrations of dexamethasone well 14 below the standard pharmacologically concentrations routinely used. The low concentrations required together with the facts that progesterone was without effect and RU 486 blocked the actions of dexamethasone strongly suggests that dexamethasone acts via glucocorticoid receptors and was not acting non-selectively via changes in membrane fluidity (Gerritsen et al., 1991) , or simply by competition for LPS binding sites (TahriJouti & Chaby, 1990) .
Further studies established that dexamethasone acted via the induction of LC1, since preperfusion of hearts with the anti-LC1 neutralising antibody LCPS1 markedly attenuated the inhibitory actions of dexamethasone. This finding supports the hypothesis that LC1 is a mediator of the action of glucocorticoids (Flower & Rothwell, 1994) and is in agreement with several reports demonstrating that neutralising antibodies to lipocortin reverse many effects of glucocorticoids including their ability to inhibit cell trafficking (Perretti et al., 1996) , paw oedema (Duncan et al., 1993) , cell division and differentiation (Croxtall & Flower, 1992) as well as the inhibitory action exerted by these steroids on hormone release from the anterior pituitary (Taylor et al., 1995) . The rapid onset of the response to dexamethasone may indicate that, in the rat heart, dexamethasone may either induce the synthesis and/or rapid translocation of pre-formed intracellular LC1 to the membrane. Additionally, dexamethasone may also increase release of LC1 from plasma membrane bound pools. Such rapid changes in cellular LC1 disposition have indeed been reported in other systems (Solito et al., 1994; Kaufman et al., 1996) .
We have previously shown that indomethacin has no effect on the response to LPS in the rat heart (Baydoun et al., 1993) suggesting that vasodilator cyclo-oxygenase products are not involved in this response. In this study we have examined the involvement of other PLA 2 -derived mediators, including PAF, in the response to LPS. Administration of PAF to animals 15 causes a similar shock syndrome to LPS (Bessin et al., 1983; Doebber et al., 1985; Mulder et al., 1993) . Furthermore, PAF release is increased in animals following LPS-administration, and PAF antagonism attenuates endotoxin-induced vasodilatation in experimental models of shock (Doebber et al., 1985; Redl et al., 1990) .
Our data suggest that PAF is a mediator of LPS-induced vasodilatation in the rat isolated perfused heart since responses to LPS were significantly reduced by WEB 2086. However, LPS may bind directly to and activate PAF receptors without the need for intermediate PAF release (Nakamura et al,1992) , an effect that presumably would also be prevented by WEB
2086.
We could not characterise the effects of exogenous PAF in our system. However, other authors have reported that exogenous PAF exerts two different effects with low doses (10 fmol -1 pmol) initiating a vasodilator response while higher doses (≥1 pmol) induce vasoconstriction (Man et al., 1990) . In our limited studies, administration of PAF to freshly isolated hearts did cause coronary vasodilatation. However, these responses were not reproducible or dose-dependent.
We investigated the role of the lipoxygenase pathway in mediating responses to LPS by examining the effect of NDGA on LPS-induced coronary vasodilatation. NDGA selectively inhibited the effect of LPS but failed to modify responses to either SNP or bradykinin.
However, NDGA has been reported to have several other actions including inhibition of PLA 2 and of PAF release (Lanni & Becker, 1985) . Thus we cannot discount the possibility that the effects of NDGA in our studies are due to inhibition of PLA 2 rather than lipoxygenase.
Although further studies utilising more selective inhibitors of lipoxygenases are required it is worth noting that 5-lipoxygenase has been implicated in the vasodilator action of PAF in the rat isolated perfused heart (Hu et al., 1991) . The 5-lipoxygenase inhibitor MK-886 (Gillard et al. 1989; Rouzer et al., 1990) was found to inhibit the response to PAF as was the leukotriene (LT) antagonist L-649,923 (Jones et al., 1986) suggesting that the effects of exogenous PAF may be mediated via the release of LT, presumably the vasodilator LT, LTB 4 . Thus, it would not be unreasonable to speculate that in our system, LPS acting independently on PAF receptors or via the release of PAF itself may activate 5-lipoxygenase pathway and presumably release LTB 4 . Whether products of the lipoxygenase pathway interact with constitutive NO synthase is a fascinating question which remains to be investigated. Cross-talk between these two pathways would clearly explain the findings that inhibitors of either lipoxygenase or NO synthase virtually abolish LPS-induced vasodilatation in the rat heart.
One other potential mechanism of action of PAF is the release of NO, via the constitutive endothelial L-arginine-NO pathway, which has been shown to contribute to the vasodilator actions of PAF in the mesenteric vasculature of the rat (Chiba et al., 1990) . Clearly an action of PAF via this pathway would account for the abrogation of the LPS response by NOS inhibitors as well as PLA 2 and PAF antagonists. Thus the release of NO may be the final end point of a multifactorial cascade activated by LPS in the coronary microvasculature of the rat.
This cascade is dependent on rapid synthesis and/or turnover of an intermediate protein which may be the coupling link between the LPS receptor and the initiation of bradykinin release and/or PLA 2 activation. A comparable dependence on protein synthesis has been reported by Petitclerc et al. (1994) who showed that rapid interleukin-1-induced vasodilatation in the rabbit isolated mesenteric artery was blocked within 15 minutes by three functionally distinct inhibitors of protein synthesis including cycloheximide. The response to interleukin-1, like the response to LPS described here, was dependent on activation of PLA 2 .
In conclusion, our data confirm that endothelial constitutive NO synthase (eNOS) can be activated acutely by LPS resulting in the release of NO in sufficient quantities to initiate coronary vasodilatation in the rat heart. This end effect also involves other intracellular events including activation of PLA 2 , which may in turn interact with eNOS via the release of PAF. These findings implicate eNOS in the vasodilatation which occurs in LPS-induced shock in both experimental models and man. However, these results may have other important implications with the acute activation of coronary vasodilatory pathways having beneficial cardioprotective rather than the deleterious effects normally associated with inflammatory responses induced by endotoxin. This applies in particular to the phenomenon of "cross tolerance" induced by endotoxin against ischaemia-reperfusion injury (Song et al., 1996) . (control) or 50 μM L-NAME (n=3). Responses were recorded to 10 μl bolus injections of 0.1 nmol BK (n=3) and 10 nmol SNP (n=3), or infusion of 5 μg.ml -1 LPS (n=3). In parallel studies, flow was reduced to 1 ml.min -1 and NO release due to LPS-treatment measured by chemiluminescent detection. ND denotes not determined, <MDL denotes below minimum detection limit, * denotes statistical significance at P<0.01 compared to respective controls. 
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